Published in Medical Letter on the CDC and FDA, April 1st, 2001
Jail inmates, who constitute a known reservoir of latent tuberculosis infection, could benefit from treatment but are often released before they can complete the traditional six-month isoniazid regimen, N.N. Bock and associates said. The researchers tested a two-month short-course of rifampin and pyrazinamide (2RZ) and found that about half of the inmates that started treatment were able to complete the regimen.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA